Introduction
Identifying biomarkers associated with long-term treatment outcomes is essential for guiding clinical decision-making, individualizing treatment, and monitoring disease activity in Crohn’s disease (CD). C-reactive protein (CRP) and faecal calprotectin (FC) are routinely measured biomarkers in CD that objectively reflect systemic and intestinal inflammation, respectively.1,2 We evaluated the association between early serum and faecal biomarker response and 1-year clinical/endoscopic outcomes in participants (pts) with CD treated with guselkumab (GUS).
Aims & Methods
Post-hoc analyses used pooled data from the Phase 3 GALAXI 2&3 trials in adults with moderately to severely active CD randomized to intravenous GUS 200mg at Week (W)0, W4, W8, followed by subcutaneous GUS 100mg every 8W (Q8W) from W16-40 or GUS 200mg Q4W from W12-44. Analyses included pts with abnormal W0 CRP (>3mg/L) or FC (>250µg/g). Biomarker response was assessed at W4, W8, and W12; CRP response was defined as CRP≤3mg/L or ≥50% reduction from W0, and FC response as FC≤250µg/g or ≥50% reduction from W0. Clinical (CD Activity Index (CDAI) score<150), endoscopic (Simple Endoscopic Score for CD [SES-CD]≤4, ≥2-point reduction from W0 in SES-CD, and no SES-CD sub-score >1), and deep (clinical and endoscopic remission) remission were evaluated at W48. For all outcomes, pts with missing data after applying intercurrent event rules were considered as non-responders. Associations between early biomarker response and W48 outcomes were assessed using univariate and multivariate logistic regression adjusted for age, sex, GUS maintenance regimen, and prior biologic treatment failure status. All p-values are nominal.
Results
Among 582 GUS-treated pts, 418 (72%) and 469 (81%), respectively, had abnormal CRP and FC levels at W0. CRP and FC response rates increased over time (W4: 57%/44%; W8: 67%/58%; W12: 69%/64%). At W48, clinical, endoscopic, and deep remission were achieved by 68%, 31%, and 34% of pts with abnormal W0 biomarker levels.
Early CRP and FC responses with GUS were associated with higher rates of clinical, endoscopic, and deep remission at W48, with effects observed as early as W4 for CRP (all p<0.01) and W8 for FC (all p<0.001) across outcomes (Table 1). These associations remained consistent in adjusted models, with CRP response from W4 onward (odds ratio [95% confidence interval]: clinical remission: 1.9 [1.2-2.9]; endoscopic remission: 2.5 [1.6-3.9]; and deep remission: 2.2 [1.4-3.5]; all p<0.01) and FC response from W8 onward (clinical remission: 2.0 [1.3-3.0]; endoscopic remission: 2.4 [1.6-3.7]; and deep remission: 2.2 [1.4-3.5]; all p<0.01) significantly associated with W48 outcomes in GUS-treated pts.
Table 1. Association between early CRP or FC response and W48 clinical/endoscopic outcomes among GUS-treated pts with CD in GALAXI 2&3
| W48 Clinical Remission | W48 Endoscopic Remission | W48 Deep Remission |
| Rates* | Unadjusted P-value | Rates* | Unadjusted P-value | Rates* | Unadjusted P-value |
CRP Response (yes vs no) | W4 | 74% vs 61% | 0.0041 | 42% vs 22% | <0.0001 | 38% vs 21% | 0.0003 |
| W8 | 74% vs 56% | 0.0003 | 41% vs 20% | <0.0001 | 37% vs 19% | 0.0003 |
| W12 | 76% vs 56% | 0.0001 | 39% vs 22% | 0.0004 | 36% vs 19% | 0.0007 |
FC Response (yes vs no)
| W4 | 72% vs 64% | 0.0620 | 38% vs 31% | 0.0924 | 34% vs 29% | 0.2941 |
| W8 | 75% vs 59% | 0.0008 | 42% vs 23% | <0.0001 | 38% vs 21% | 0.0002 |
| W12 | 74% vs 62% | 0.0249 | 43% vs 18% | <0.0001 | 39% vs 18% | <0.0001 |
*Rates are shown among those achieving vs not achieving early biomarker response
Conclusion
In adults with moderately to severely active CD in GALAXI 2&3, early serum and faecal biomarker responses with GUS were significantly associated with 1-year clinical, endoscopic and deep remission, suggesting potential utility in informing longer-term treatment outcomes.
References
- DB. Sachar, et al., Inflammatory Bowel Diseases 20.12 (2014): 2511-2518.
- MH. Mosli et al., Official journal of the American College of Gastroenterology| ACG 110.6 (2015): 802-819.
Disclosure
MFe: Research grants from AbbVie, EG Pharma, Celltrion, Johnson & Johnson, Pfizer, Takeda and Viatris; Consultancy fees from AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Johnson& Johnson, MRM Health, Merck Sharp and Dohme, Pfizer, Takeda and ThermoFisher; Speakers’ fees from AbbVie, Biogen, Boehringer Ingelheim, Dr Falk Pharma, Ferring, Johnson & Johnson, Merck Sharp and Dohme, Pfizer, Takeda, Truvion Healthcare and Viatris
AA: Consulting fees from AbbVie, Abivax, Alfa Sigma, Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Enthera, Ferring, Galapagos, Gilead, Giuliani, Johnson & Johnson, Lionhealth, MSD, Nestlé, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sanofi, Sandoz, Takeda, Teva Pharmaceuticals, Tillots Pharma; Speaker’s fees from AbbVie, Abivax, AG Pharma, Alfa Sigma, Biogen, Bristol-Myers Squibb, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Johnson & Johnson, Lionhealth, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Teva Pharmaceuticals; Research support from Biogen, MSD, Takeda, and Pfizer; Non-financial support from AbbVie, Johnson & Johnson, MSD, Pfizer, Takeda.
RA: Speaker, consultant, or received research grants: AbbVie, Abivax, AlfaSigma, Arena Pharmaceuticals, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Dr Falk Pharma, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Johnson & Johnson, Eli Lilly, Materia Prima, Merck Sharpe & Dohme, Pfizer, Roche Pharma, Takeda Pharma, Viatris.
TR: research and educational grants and/or speaker/consultation fees: Abbvie, Alfasigma, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Domain Therapeutics, Eli Lilly, Ferring, Galapagos, Gilead, GlaxoSmithKline, Heptares, Johnson & Johnson, LabGenius, MonteRosa, Mylan, Merck Sharpe & Dohme, Novartis, Numab, Pfizer, Roche, Sandoz, Scientia, Takeda, UCB and XAP therapeutics.
RVP, MN, JVD, VM: Employee: Johnson & Johnson; May own stocks/stock options: Johnson & Johnson.
MFu: Grant: Pfizer; Personal Fees: AbbVie, Amgen, Arena, Biogen, Boehringer, Celgene, CTMA, Eli Lilly, Ferring, Fresenius, Galapagos, Gilead, Hospira, Johnson & Johnson, MSD, Mylan, Pfizer, Sandoz, Takeda, and Tillots; Non-financial Support: AbbVie, Ferring, Galapagos, Johnson & Johnson, MSD, Pfizer, and Takeda.